Drug interactions associated with pulmonary arterial hypertension therapy

Trang H. Au, Nancy L. Fagan, Dan Schuller, Mark A. Malesker

Research output: Contribution to specialist publicationArticle

Abstract

Pulmonary arterial hypertension (PAH) is a progressively fatal disease of the small pulmonary arteries. In the last two decades, pharmacotherapeutic advances have improved prognosis. Standard treatment of PAH includes anticoagulants, diuretics, digoxin, and calcium channel blockers. Advanced treatment of PAH includes phosphodiesterase type 5 inhibitors, endothelin antagonists, and prostanoids. Combination therapy can produce additive and synergistic benefit. However, drug interactions may occur among PAH therapies or between medications indicated for PAH and agents used for concomitant illnesses. These interactions may necessitate medication adjustment or are serious enough to limit treatment options. Pulmonary arterial hypertension (PAH) is a complex disorder of the small pulmonary arteries. It is characterized by vascular proliferation and obstructive remodeling, which reduces blood flow through the pulmonary arterial circulation, increases pulmonary vascular resistance, and eventually causes right heart failure. The hemodynamic definition of PAH is a resting mean pulmonary arterial pressure (mPAP) of ≥25 mmHg and a pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg.1,2.

Original languageEnglish
Volume38
No10
Specialist publicationU.S. Pharmacist
StatePublished - 2013

Fingerprint

Drug interactions
Phosphodiesterase 5 Inhibitors
Capillarity
Digoxin
Calcium Channel Blockers
Hemodynamics
Drug Interactions
Diuretics
Pulmonary Hypertension
Anticoagulants
Prostaglandins
Blood
Pulmonary Artery
Therapeutics
Pulmonary Wedge Pressure
Pulmonary Circulation
Endothelin Receptor Antagonists
Vascular Resistance
Blood Vessels
Arterial Pressure

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacy

Cite this

Drug interactions associated with pulmonary arterial hypertension therapy. / Au, Trang H.; Fagan, Nancy L.; Schuller, Dan; Malesker, Mark A.

In: U.S. Pharmacist, Vol. 38, No. 10, 2013.

Research output: Contribution to specialist publicationArticle

Au, Trang H. ; Fagan, Nancy L. ; Schuller, Dan ; Malesker, Mark A. / Drug interactions associated with pulmonary arterial hypertension therapy. In: U.S. Pharmacist. 2013 ; Vol. 38, No. 10.
@misc{6343a3ccbd0f43dc9306869471a014e6,
title = "Drug interactions associated with pulmonary arterial hypertension therapy",
abstract = "Pulmonary arterial hypertension (PAH) is a progressively fatal disease of the small pulmonary arteries. In the last two decades, pharmacotherapeutic advances have improved prognosis. Standard treatment of PAH includes anticoagulants, diuretics, digoxin, and calcium channel blockers. Advanced treatment of PAH includes phosphodiesterase type 5 inhibitors, endothelin antagonists, and prostanoids. Combination therapy can produce additive and synergistic benefit. However, drug interactions may occur among PAH therapies or between medications indicated for PAH and agents used for concomitant illnesses. These interactions may necessitate medication adjustment or are serious enough to limit treatment options. Pulmonary arterial hypertension (PAH) is a complex disorder of the small pulmonary arteries. It is characterized by vascular proliferation and obstructive remodeling, which reduces blood flow through the pulmonary arterial circulation, increases pulmonary vascular resistance, and eventually causes right heart failure. The hemodynamic definition of PAH is a resting mean pulmonary arterial pressure (mPAP) of ≥25 mmHg and a pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg.1,2.",
author = "Au, {Trang H.} and Fagan, {Nancy L.} and Dan Schuller and Malesker, {Mark A.}",
year = "2013",
language = "English",
volume = "38",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Drug interactions associated with pulmonary arterial hypertension therapy

AU - Au, Trang H.

AU - Fagan, Nancy L.

AU - Schuller, Dan

AU - Malesker, Mark A.

PY - 2013

Y1 - 2013

N2 - Pulmonary arterial hypertension (PAH) is a progressively fatal disease of the small pulmonary arteries. In the last two decades, pharmacotherapeutic advances have improved prognosis. Standard treatment of PAH includes anticoagulants, diuretics, digoxin, and calcium channel blockers. Advanced treatment of PAH includes phosphodiesterase type 5 inhibitors, endothelin antagonists, and prostanoids. Combination therapy can produce additive and synergistic benefit. However, drug interactions may occur among PAH therapies or between medications indicated for PAH and agents used for concomitant illnesses. These interactions may necessitate medication adjustment or are serious enough to limit treatment options. Pulmonary arterial hypertension (PAH) is a complex disorder of the small pulmonary arteries. It is characterized by vascular proliferation and obstructive remodeling, which reduces blood flow through the pulmonary arterial circulation, increases pulmonary vascular resistance, and eventually causes right heart failure. The hemodynamic definition of PAH is a resting mean pulmonary arterial pressure (mPAP) of ≥25 mmHg and a pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg.1,2.

AB - Pulmonary arterial hypertension (PAH) is a progressively fatal disease of the small pulmonary arteries. In the last two decades, pharmacotherapeutic advances have improved prognosis. Standard treatment of PAH includes anticoagulants, diuretics, digoxin, and calcium channel blockers. Advanced treatment of PAH includes phosphodiesterase type 5 inhibitors, endothelin antagonists, and prostanoids. Combination therapy can produce additive and synergistic benefit. However, drug interactions may occur among PAH therapies or between medications indicated for PAH and agents used for concomitant illnesses. These interactions may necessitate medication adjustment or are serious enough to limit treatment options. Pulmonary arterial hypertension (PAH) is a complex disorder of the small pulmonary arteries. It is characterized by vascular proliferation and obstructive remodeling, which reduces blood flow through the pulmonary arterial circulation, increases pulmonary vascular resistance, and eventually causes right heart failure. The hemodynamic definition of PAH is a resting mean pulmonary arterial pressure (mPAP) of ≥25 mmHg and a pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg.1,2.

UR - http://www.scopus.com/inward/record.url?scp=84886797006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886797006&partnerID=8YFLogxK

M3 - Article

VL - 38

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -